For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Botulinum toxin type A - Migraine (prevention)
PAD Profile : Botulinum toxin type A - Migraine (prevention) Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Flunarizine dihydrochloride
- Pizotifen malate
- Erenumab
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Candesartan cilexetil
- Clonidine hydrochloride
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Area Prescribing Committee agreed to adopt the South West London (SWL) migraine prophylaxis drug pathway for chronic and episodic migraine.
NOTE: updates and new additions to the pathway are provided in addendums at the end of the document.
See the Migraine (prophylaxis) Drug Pathway for full information.
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of botulinum toxin type A for the prevention of headaches in adults with chronic migraine in line with NICE TA260 (June 2012) and the locally agreed treatment pathway below.
Prescribing will be by hospital specialists only, in line with NICE TA260 using Blueteq initiation and continuation forms. Botulinum toxin type A will be considered RED on the traffic light system.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication